Acciones AXIM Biotechnologies, Inc. Other OTC
Acciones
AXIM
US05463V1008
Biotecnología e investigación médica
Ventas 2022 | 8,88 mil 8,32 mil | Ventas 2023 | 39,52 mil 37,07 mil | Capitalización | 4,52 M 4,24 M |
---|---|---|---|---|---|
Resultado Neto 2022 | -6 M -5,63 M | Resultado Neto 2023 | -8 M -7,5 M | VE / Ventas 2022 | 1.218 x |
Deuda neta 2022 | 5,64 M 5,29 M | Deuda neta 2023 | 5,74 M 5,38 M | VE / Ventas 2023 | 259 x |
P/E ratio 2022 |
-0,69
x | P/E ratio 2023 |
-0,48
x | Empleados | - |
Rendimiento 2022 * |
-
| Rendimiento 2023 |
-
| Flotante | 71,61 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 29/06/16 |
Kurt Phinney
COO | Chief Operating Officer | - | 23/05/23 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 18/05/17 |
Director/Board Member | 76 | 18/05/17 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+0,17 % | 42,86 mil M | |
+10,92 % | 42,74 mil M | |
+44,30 % | 41,36 mil M | |
-6,20 % | 27,68 mil M | |
+5,23 % | 25,15 mil M | |
-24,79 % | 18,63 mil M | |
+26,69 % | 12,37 mil M | |
-3,13 % | 11,92 mil M | |
+6,57 % | 11,21 mil M |